Cervical Cancer

>

Latest News

Tislelizumab/Chemo Yields Antitumor Activity in Advanced Cervical Cancer
Tislelizumab/Chemo Yields Antitumor Activity in Advanced Cervical Cancer

March 16th 2024

A phase 2 trial showed favorable antitumor activity when tislelizumab plus chemotherapy was used for patients with locally advaned cervical cancer.

Disparities in Cervical Cancer by Socioeconomic Status
Disparities in Cervical Cancer by Socioeconomic Status

March 16th 2024

Treatment with simple hysterectomy reduces the incidence of urinary incontinence compared with radical hysterectomy in patients with low-risk cervical cancer.
Simple Hysterectomy Noninferior Vs Radical Hysterectomy in Cervical Cancer

March 11th 2024

Tisotumab vedotin may become the first antibody drug conjugate to receive marketing authorization in the European Union as a treatment for those with cervical cancer.
EMA Validates Tisotumab Vedotin Marketing Application in Cervical Cancer

February 5th 2024

Treatment with pembrolizumab plus chemotherapy with or without bevacizumab yields an overall survival improvement regardless of squamous or nonsquamous cervical cancer histology.
Pembrolizumab Combo Improves OS in Metastatic Cervical Cancer Subgroups

January 25th 2024

Video Interviews
Podcasts
The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.
Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.
Oncology Peer Review On-The-Go

More News